Adamax (Davunetide/NAP) × glowaminos peptides — lab test, July 2026
COA ACC-2026-6933 matches ILS Laboratories's public record. So this test doesn't rest on our review alone — the lab confirms it too.
SENNOWNETest results
This is a purity and identity analysis. Sterility, endotoxins, and heavy metals were not screened — a high purity figure says nothing about those.
About this test
Label 15 mg · Lab measured 15.92 mg
106% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 4 mg using the measured mass, against 3.8 mg on the label — 6% more.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
| Report number | ACC-2026-6933 |
|---|---|
| Portal lookup | ✓ Lab-verified |
| Checked | 10 Aug 2026date taken from the record, not from a logged check |
| Checked by | Peptigrity staff, against the lab's portal |
| PDF vs portal | ILS Laboratories's portal shows validity only |
| Weight | Counts as one lab test |
Independent HPLC purity analysis of Adamax from glowaminos peptides, performed by ILS Laboratories on July 7, 2026. Reported purity: 99.65%. Net content: 15.92 mg against 15 mg labeled (106% of label). Heavy metals: ICP-MS: all elements below limit (PASS). Batch GL-010190. Sample source: shop-provided. Certificate of analysis attached.
Certificate of analysis
Other lots of Adamax (Davunetide/NAP) from glowaminos peptides
| Lot | Tested | Lab | Purity | vs label | Status |
|---|---|---|---|---|---|
| GL-010195 | 9 Jul 2026 | ILS Laboratories | 99.88% | 107% | ✓ Lab-verified |
| GL-010162 | 16 Jun 2026 | ILS Laboratories | 99.73% | 105% | ✓ Lab-verified |
| GL-010090 | 24 Apr 2026 | ILS Laboratories | 99.77% | 105% | ✓ Lab-verified |
Batches this shop has published a certificate for, newest first. A lot whose printed value cannot identify a batch is not listed.
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion